Jefferies International Reconfirms The “Buy” Rating They’ve had for BTG PLC (LON:BTG) Shares

May 16, 2018 - By Tina Thibodeau

BTG plc (LON:BTG) Logo

BTG PLC (LON:BTG) Rating Reaffirmed

In a research report published by Jefferies International on Wednesday, 16 May, The Rating on BTG PLC (LON:BTG) shares of a ‘”Buy”‘ was reconfirmed.

BTG plc (LON:BTG) Ratings Coverage

Among 5 analysts covering BTG PLC (LON:BTG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. BTG PLC has GBX 900 highest and GBX 650 lowest target. GBX 772.50’s average target is 27.16% above currents GBX 607.5 stock price. BTG PLC had 16 analyst reports since November 22, 2017 according to SRatingsIntel. Numis Securities maintained the stock with “Buy” rating in Thursday, February 1 report. The stock of BTG plc (LON:BTG) earned “Buy” rating by Jefferies on Tuesday, May 15. JP Morgan maintained it with “Neutral” rating and GBX 680 target in Friday, April 6 report. The stock has “Neutral” rating by JP Morgan on Wednesday, May 16. As per Wednesday, January 24, the company rating was maintained by Numis Securities. The rating was maintained by Numis Securities with “Buy” on Friday, December 8. The firm earned “Neutral” rating on Wednesday, November 22 by JP Morgan. Peel Hunt maintained BTG plc (LON:BTG) on Tuesday, May 15 with “Hold” rating. Peel Hunt maintained it with “Hold” rating and GBX 700 target in Thursday, February 1 report. The rating was maintained by JP Morgan with “Neutral” on Friday, December 8.

The stock increased 2.88% or GBX 17 during the last trading session, reaching GBX 607.5. About 316,876 shares traded. BTG plc (LON:BTG) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts await BTG plc (LON:BTG) to report earnings on August, 8. BTG’s profit will be $154,601 for 3796.88 P/E if the $0.04 EPS becomes a reality. After $0.06 actual earnings per share reported by BTG plc for the previous quarter, Wall Street now forecasts -33.33 % negative EPS growth.

BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. The company has market cap of 2.35 billion GBP. It operates through three divisions: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. It has a 31.97 P/E ratio. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.